Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Stocks in this Quantisnow insightHealth Care
Historical context for FATE
Across the 23 sessions after earlier FATE headlines, the stock closed higher 10 times and lower 12 times, with a median move of 5.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | FATE | SPY |
|---|---|---|---|
| Jun 3, 2026 | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | -13.6% | -0.7% |
| Jun 1, 2026 | Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting | -3.5% | +0.3% |
| May 21, 2026 | Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases | +14.1% | +0.2% |
| May 19, 2026 | Jefferies resumed coverage on Fate Therapeutics | +9.2% | -0.7% |
| May 13, 2026 | Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | -5.1% | +0.6% |
| May 11, 2026 | Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting | -8.8% | +0.2% |
Quantisnow market dataNASDAQ
FATE
Fate Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2013
Get push alerts for FATE
Full FATE profile on Quantisnow Follow FATE and get a push notification the moment its next story breaks.